ClinicalTrials.gg

Program

venglustat

Also written as “Venglustat”, “Venglustat (GZ402671)” and “GZ/SAR402671”.

In Sanofi's pipeline, Oral GCS inhibitor. Its studies are mostly in Fabry Disease · Gaucher Disease · Polycystic Kidney, Autosomal Dominant · Tay-Sachs Disease · Liver Diseases, led by Sanofi.

Furthest: phase 3, since May 1, 201819 company-led studies, 5 open or runningNext primary completion: Jan 14, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi195 open or runningphase 3since May 1, 2018Aug 24, 2012Jan 14, 2030phase 3 · NCT07927140
  • Named in Sanofi’s own pipeline as venglustat, phase 4, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Aug 24, 2012.

  1. Jun 30, 2015Phase 2 study in Fabry DiseaseNCT02489344 · 8 enrolled · United States, France, Poland and more
  2. Jul 20, 2016Phase 2 study in Gaucher DiseaseNCT02843035 · 12 enrolled · United States, Germany, Japan and more
  3. Sep 14, 2016Phase 2 study in Parkinson DiseaseNCT02906020 · 273 enrolled · United States, Austria, Canada and more
  4. May 1, 2018Phase 3 study in Polycystic Kidney, Autosomal DominantNCT03523728 · 478 enrolled · United States, Argentina, Australia and more
  5. Sep 26, 2018Phase 1 study in Polycystic Kidney, Autosomal DominantNCT03687554 · 24 enrolled · United States
  6. Jan 6, 2020Phase 3 study in Tay-Sachs DiseaseNCT04221451 · 75 enrolled · United States, Argentina, Brazil and more
  7. Jan 8, 2021Phase 3 study in Kidney Diseases, CysticNCT04705051 · 24 enrolled · United States, Australia, Belgium and more
  8. Oct 20, 2021Phase 3 study in Fabry DiseaseNCT05206773 · 122 enrolled · United States, Argentina, Australia and more
  9. Jan 20, 2022Phase 3 study in Gaucher DiseaseNCT05222906 · 43 enrolled · United States, Argentina, Canada and more
  10. Feb 3, 2022Phase 1 study in Disorders of Sphingolipid MetabolismNCT05238714 · 6 enrolled · United Kingdom
  11. Mar 4, 2022Phase 3 study in Fabry DiseaseNCT05280548 · 104 enrolled · United States, Austria, Canada and more
  12. Jan 30, 2023Phase 1 study in Liver DiseasesNCT05718258 · 26 enrolled · United States, Germany
  13. May 13, 20243 phase 1 studies in Healthy VolunteersNCT06421714, NCT06418620, NCT06418607
  14. Jun 24, 2026Phase 3 study in Gaucher DiseaseNCT07927140 · 18 planned

Ahead

  1. Jan 14, 2030Primary completion: phase 3 study in Gaucher DiseaseNCT07927140

TargetBeta

“Oral GCS inhibitor”the company's pipeline, read by Claude · source
“Ceramide glucosyltransferase inhibitor”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07927140Gaucher Disease3Not yet recruitingJan 14, 203018
NCT06421714Healthy Volunteers · United States1CompletedOct 14, 20188
NCT06418620Healthy Volunteers · United States1CompletedAug 7, 20209
NCT06418607Healthy Volunteers · United States1CompletedJul 13, 202065
NCT05718258Liver Diseases · United States, Germany1CompletedJan 29, 202426
NCT05280548Fabry Disease · United States, Austria, Canada and more3Active, not recruitingMay 22, 2026104
NCT05238714Disorders of Sphingolipid Metabolism · United Kingdom1CompletedJun 26, 20206
NCT05222906Gaucher Disease · United States, Argentina, Canada and more3Active, not recruitingOct 2, 202543
NCT05206773Fabry Disease · United States, Argentina, Australia and more3Active, not recruitingDec 17, 2025122
NCT04705051Kidney Diseases, Cystic · United States, Australia, Belgium and more3TerminatedJul 13, 202124
NCT04221451Tay-Sachs Disease · United States, Argentina, Brazil and more3TerminatedDec 26, 202475
NCT03687554Polycystic Kidney, Autosomal Dominant · United States1CompletedFeb 27, 201924
NCT03523728Polycystic Kidney, Autosomal Dominant · United States, Argentina, Australia and more3TerminatedAug 3, 2021478
NCT02906020Parkinson Disease · United States, Austria, Canada and more2TerminatedDec 18, 2020273
NCT02843035Gaucher Disease · United States, Germany, Japan and more2Active, not recruitingOct 30, 202612
NCT02489344Fabry Disease · United States, France, Poland and more2CompletedNov 20, 20188
NCT02228460Fabry Disease · United States, France, Poland and more2CompletedSep 201611
NCT01710826Healthy · United States1CompletedFeb 201336
NCT01674036Healthy Volunteer · United States1CompletedJan 201363

How it is read

Names in the registry

  • “Venglustat”, 7 entries
  • “Venglustat (GZ402671)”, 3 entries
  • “GZ/SAR402671”, 2 entries
  • “Genz-682452”, 2 entries
  • “venglustat (GZ402671)”, 1 entry

Codes read as this program: SAR402671.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.